

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5 Attorney Docket Number 51326-00005 NAT

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/RI/		3,888,837	06/10/75	Tsumita et al.	
		3,943,119	03/09/76	Tsumita et al.	
		4,123,427	10/31/78	Dniel	
		4,285,931	08/25/81	Limjuco et al.	
		4,460,503	07/17/84	Savrda et al.	
		4,724,144	02/09/88	Rook et al.	
		4,777,130	10/11/88	Maes	
		4,889,800	12/26/89	Shinnick et al.	
		4,906,742	03/06/90	Young et al.	
		4,952,395	08/28/90	Shinnick et al.	
		4,965,192	10/23/90	Maes	
		4,976,958	12/11/90	Shinnick et al.	
		5,108,745	04/28/92	Horwitz	
		5,154,923	10/13/92	Van Eden et al.	
		5,169,940	12/08/92	Patarroyo	
		5,171,839	12/15/92	Patarroyo	
		5,225,324	07/06/93	McFadden et al.	
		5,254,459	10/19/93	Patarroyo	
↓		5,268,170	12/07/93	Van Eden et al.	
		6,013,660	01/11/00	Horwitz et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
/RI/		EP	0499003		08/1992			
↓		EP	0519218		12/1992			
↓		GB	2239246		06/1991			
		WO	85/03639		08/1985			

Examiner Signature	/Roy Issac/ (04/05/2007)	Date Considered	04/05/2007
--------------------	--------------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>6</sup>Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5 Attorney Docket Number 51326-00005 NAT

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
/RI/		WO	88/02027		03/1988			
		WO	88/05823		08/1988			
		WO	88/06626		09/1988			
		WO	89/05825		06/1989			
		WO	89/12455		12/1989			
		WO	90/00594		01/1990			
		WO	90/02564		03/1990			
		WO	90/10449		09/1990			
		WO	90/15873		12/1990			
		WO	91/04272		04/1991			
		WO	91/14448		10/1991			
		WO	92/01783		02/1992			
		WO	92/01796		02/1992			
		WO	92/04462		03/1992			
		WO	92/16628		10/1992			
		WO	92/21376		12/1992			
		WO	92/21697		12/1992			
		WO	92/22326		12/1992			
		WO	93/07897		04/1993			
		WO	93/14118		07/1993			
		WO	93/14789		08/1993			
		WO	94/02508		02/1994			
		WO	95/01440		01/1995			
		WO	95/01441		01/1995			
✓		WO	95/14713		06/1995			
		WO	04/45539		06/2004			

Examiner Signature	/Roy Issac/ (04/05/2007)	Date Considered	04/05/2007
--------------------	--------------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5 Attorney Docket Number 51326-00005 NAT

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/RI/		Abbott et al., "Structure prediction and active site analysis of the metal binding determinants in $\gamma$ -glutamylcysteine synthetase," J. Biol. Chem. 276:42099-107 (2001)	
		Bartsch et al., "Stereospecific production of the herbicide phosphinothricin (Glufosinate) by transamination: cloning, characterization, and overexpression of the gene encoding a phosphinothricin-specific transaminase in Escherichia coli," App. Environ. Microbiol. 56:7-12 (1990)	
		Campbell et al., "Analytical and Preparative Separation of Diastereomers of L-Buthionine-SR-Sulfoximine, a Potent Inhibitor of Glutathione Biosynthesis," Anal. Biochem. 194:268-77 (1991)	
		Chamberlin et al., "Design and synthesis of conformationally constrained inhibitors of highly-affinity, sodium dependent glutamate transporters," Meth. Enzymol. 296:175-89 (1998)	
		Cooper et al., "Enzymatic reactions of methionine sulfoximine. Conversion to the corresponding $\alpha$ -imino and $\alpha$ -keto acids and to $\alpha$ -ketobutyrate and methane sulfinimide," J. Biol. Chem. 251:6674-82 (1976)	
		Database CAPLUS, Chemical Abstracts on STN, (Columbus Ohio, USA), Abstract No. 50:49285, SVACHULOVÁ, Effect of L-Ascorbic Acid on the Growth and Metabolism of Mycobacteria Tuberculosis, Rozhledy Tuberk, 1956, Vol. 16, pp. 203-206	
		Eisenberg et al., "Structure-function relationships of glutamine synthetases," Biochim. Biophys. Acta. 1477:122-45 (2000)	
		Gershoff et al., "The relative effect of methionine sulfoximine on different animal species," J. Nutr. 45:451-8 (1951)	
		Gill et al., "Multicopy crystallographic refinement of a relaxed glutamine synthetase from Mycobacterium tuberculosis highlights flexible loops in the enzymatic mechanism and its regulation," Biochemistry 41:9863-72 (2002)	
		Gill et al., "The crystal structure of phosphinothricin in the active site of glutamine synthetase illuminates the mechanism of enzyme inhibition," Biochemistry 40:1903-12 (2001)	
↓		Griffith "Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione biosynthesis," J. Biol. Chem. 257:13704-12 (1982)	

Examiner Signature	/Roy Issac/ (04/05/2007)	Date Considered	04/05/2007
--------------------	--------------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5 Attorney Docket Number 51326-00005 NAT

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/RI/		Griffith et al., "Differential inhibition of glutamine and $\gamma$ -glutamylcysteine synthetases by $\alpha$ -alkyl analogs of methionine sulfoximine that induce convulsions," J. Biol. Chem. 253:2333-8 (1978)	
		Griffith et al., "Inhibition of glutathione biosynthesis by prothionine sulfoximine (S-n Propyl-Homocysteine Sulfoximine), a selective inhibitor of $\gamma$ -glutamylcysteine synthetase," J. Biol. Chem. 254:1205-10 (1979)	
		Griffith et al., "Potent and Specific Inhibition of Glutathione Synthesis by Buthionine Sulfoximine (S-n-Butyl-Homocysteine Sulfoxime)," J. Biol. Chem. 254:7558-60 (1979)	
		Griffith et al., "Vitamin C protects adult guinea pigs against tissue damage and lethality caused by buthionine sulfoximine-mediated glutathione depletion," FASEB J. 5:A1182 (1991)	
		Griffith, Amino acid sulfoximines: $\alpha$ -ethylmethionine sulfoximine. Meth Enzymol 143:286-91, 1987	
		Griffith et al., Resolution of cysteine and methionine enantiomers, Meth Enzymol 143:166-72, 1987	
		Harth et al., "Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamine/glutamate cell wall structure, and bacterial replication," Proc. Natl. Acad. Sci. USA 97:418-23 (2000)	
		Hoerlein "Glufosinate (phosphothrinicin), a natural amino acid with unexpected herbicidal properties," Rev. Environ. Contamin. Toxicol. 138:73-145 (1994)	
		Liaw et al., "Structural Model for the Reaction Mechanism of Glutamine Synthetase, Based on Five Crystal Structures of Enzyme-Substrate Complexes," Biochemistry 33:675-81 (1994)	
		Logusch et al., "Inhibition of Escherichia coli glutamine synthetase by $\alpha$ - and $\gamma$ -substituted phosphinotricins," Biochemistry 29:366-72 (1990)	
		Logusch et al., "Substrate variability as a factor in enzyme inhibitor design: Inhibition of ovine brain glutamine synthetase by $\alpha$ - and $\gamma$ -substituted phosphinotricins," Biochemistry 28:3043-51 (1989)	
✓		Manning et al., "Identification of L-Methionine-S-sulfoximine as the Diastereomer of L-Methionine-SR-sulfoximine that Inhibits Glutamine Synthetase," Biochemistry 8:2681-5 (1969)	

Examiner Signature	/Roy Issac/ (04/05/2007)	Date Considered	04/05/2007
--------------------	--------------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5 Attorney Docket Number 51326-00005 NAT

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/RI/		Matsumura et al., "Glufosinate ammonium induces convulsions through N-methyl-D-aspartate receptors in mice," Neurosci. Lett. 304:123-5 (2001)	
		McBean "Inhibition of glutamate transporter and glial enzymes in rat striatum by gioxin, [alpha]amino adipate," Br. J. Pharm., 113:536-40 (1994)	
		Meister "Mitochondrial changes associated with glutathione deficiency," Biochim. Biophys. Acta. 1271:35-42 (1975)	
		Nakaki et al., "Glufosinate ammonium stimulates nitric oxide production through N-methyl D-aspartate receptors in rat cerebellum," Neurosci. Lett. 290:209-12 (2000)	
		Proler et al., "The methionine sulfoximine syndrome in the cat," Epilepsia 3:117-30 (1962)	
		Rowe et al., "Identification of L-Methionine-S-Sulfoximine as the Convulsant Isomer of Methionine Sulfoximine," Proc. Natl. Acad. Sci. USA 66:500-6 (1970)	
		Tate et al., "Glutamine Synthetases of Mammalian Liver and Brain. In the Enzymes of Glutamine Metabolism," (S. Prusiner and E.R. Stadtman, eds.) Academic Press, NY 77-127 (1973)	
		Tokutake et al., "Design, Synthesis and Evaluation of Transition-state Analogue Inhibitors of Escherichia coli $\gamma$ -Glutamylcysteine Synthetase," Biorganic Med. Chem. 6:1935-53 (1998)	
		Tumani et al., Purification and immunohistochemical characterization of human brain glutamine synthetase and its detection in cerebrospinal fluid and serum by sandwich enzyme immunoassay," J. Immunol. Meth. 188:155-63 (1995)	
↓		Winholz et al., ed., "The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, Tenth Ed.," Pub. Merck & Co., Inc. Rahway, N.J. USA, pp. 745-6 Abstract No. 5032 (1983)	

Examiner Signature	/Roy Issac/ (04/05/2007)	Date Considered	04/05/2007
--------------------	--------------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.